1. Search Result
Search Result
Results for "

Ace 3 Inhibitors

" in MCE Product Catalog:

158

Inhibitors & Agonists

1

Screening Libraries

4

Fluorescent Dye

1

Biochemical Assay Reagents

39

Peptides

5

Inhibitory Antibodies

22

Natural
Products

24

Recombinant Proteins

23

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Area
  • HY-P99920
    Efmitermant alfa

    Ace083

    Inhibitory Antibodies Others
    Efmitermant alfa (ACE-083) is a locally acting, follistatin-based fusion protein. Efmitermant alfa also is a muscle-promoting agent. Efmitermant alfa can be used for the research of muscle disorders.
  • HY-P99590
    Sotatercept

    Ace-011

    TGF-β Receptor Cancer Inflammation/Immunology
    Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions.
  • HY-P99720
    Luspatercept

    Ace-536; luspatercept–aamt

    TGF-beta/Smad Metabolic Disease
    Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia.
  • HY-P99346
    Regdanvimab

    CT-P59

    SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
  • HY-P9801
    Anti-Spike-RBD mAb

    SARS-CoV-2 (2019-nCoV) Spike RBD Antibody

    SARS-CoV Infection
    Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment.